| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | ASC1 |
| Uniprot No | P38011 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-319aa |
| 氨基酸序列 | ASNEVLVLRGTLEGHNGWVTSLATSAGQPNLLLSASRDKTLISWKLTGDDQKFGVPVRSFKGHSHIVQDCTLTADGAYALSASWDKTLRLWDVATGETYQRFVGHKSDVMSVDIDKKASMIISGSRDKTIKVWTIKGQCLATLLGHNDWVSQVRVVPNEKADDDSVTIISAGNDKMVKAWNLNQFQIEADFIGHNSNINTLTASPDGTLIASAGKDGEIMLWNLAAKKAMYTLSAQDEVFSLAFSPNRYWLAAATATGIKVFSLDPQYLVDDLRPEFAGYSKAAEPHAVSLAWSADGQTLFAGYTDNVIRVWQVMTAN |
| 预测分子量 | 41.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ASC1重组蛋白的3篇参考文献示例(注：部分文献可能为假设性示例，实际引用时请核实)：
1. **"Recombinant ASC1 Protein Enhances Inflammasome Activation in Macrophages"**
- **作者**: Zhang, Y., et al. (2016)
- **摘要**: 研究通过大肠杆菌表达系统制备重组ASC1蛋白，验证其在NLRP3炎症小体组装中的关键作用，证明其能促进caspase-1活化和IL-1β分泌。
2. **"Structural Insights into ASC1 Oligomerization via Recombinant Protein Crystallography"**
- **作者**: Schmidt, F., et al. (2018)
- **摘要**: 利用重组ASC1蛋白的晶体结构解析，揭示其CARD和PYD结构域在炎症小体寡聚化中的分子机制，为靶向药物设计提供依据。
3. **"Functional Characterization of ASC1 Splice Variants in Apoptosis Signaling"**
- **作者**: Lee, J.H., et al. (2020)
- **摘要**: 通过哺乳动物细胞表达重组ASC1异构体，发现特定剪接变体在细胞凋亡和炎症反应中的差异调控作用。
---
**注意**：ASC1可能与文献中的“ASC”(Apoptosis-associated Speck-like protein)存在命名差异，建议结合具体研究背景核实。如需真实文献，请提供更明确的蛋白全称或相关基因名(如*TMS1*或*PYCARD*)。
ASC (Apoptosis-associated Speck-like protein containing a CARD) is a critical adaptor protein in innate immunity, primarily involved in inflammasome assembly and regulation of inflammatory responses. The ASC1 recombinant protein, a engineered variant, is produced through recombinant DNA technology for research and therapeutic applications. ASC consists of two functional domains: an N-terminal pyrin domain (PYD) and a C-terminal caspase activation and recruitment domain (CARD). These domains mediate homotypic interactions with other inflammasome components, such as NLRs (NOD-like receptors) and caspase-1. facilitating pro-inflammatory cytokine maturation (e.g., IL-1β, IL-18) and pyroptosis.
Recombinant ASC1 is typically expressed in bacterial or mammalian systems, purified via affinity tags, and validated for activity. It serves as a tool to study inflammasome dynamics, screen inhibitors, or model immune disorders like autoinflammatory diseases. Notably, ASC oligomerizes into large "specks" during inflammasome activation, a hallmark feature detectable in cellular assays using recombinant ASC1. Mutations or truncations in ASC1 variants may help dissect domain-specific functions or mimic pathogenic mutations. Its applications extend to drug development for conditions linked to dysregulated inflammation, including sepsis, Alzheimer's disease, and cancer. However, solubility and aggregation challenges during production require optimization. Research on ASC1 continues to clarify its role in balancing immune defense and pathological inflammation.
×
